RE:RE:MBC phase 3
Hello Noteable, you are good but not always up to date on everything. And I do appreciate what you have to offer to the boards.
From the August sedar report which you can look up to find the prospectus in regards to the proceeds fromt the recent financing.
Breast Cancer Commence the regulatory and planning process for a Phase 3 clinical study investigating the combination of pelareorep and paclitaxel versus paclitaxel monotherapy for the treatment of late-stage HR+/HER2- metastatic breast cancer with the intent to support registration. Subject to FDA feedback, we estimate this Phase 3 breast cancer study will include the dual endpoints of PFS and OS and enroll roughly 550 patients. The proceeds from the Offering are anticipated to fund the regulatory process and we expect to receive FDA feedback on this Phase 3 study in the first half of 2024, the anticipated cost of which is US$0.5 million.
I have also reached out to onc for clarification in regards to the AN deal and they sent me a link to the prospectus but cannot get clarification yet as to whether or not the payements are triggered by AN doing a phase 3 or ONC or either one....but it would appear that it is a phase 3 trial and not the trials leading up to it from my take on the reading of the prospectus